Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- All Applicants Should Be Given Access to Prior Assessment System: JPMA
August 30, 2010
- Terumo: Sales Up 4.9% Driven by Strong Overseas Sales
August 30, 2010
- Fujitsu Aims at 30% Market Share with Cloud Services for Pharma Industry
August 30, 2010
- Asahi Kasei Pharma: Sales Down for Mainstay Products
August 30, 2010
- 80% of Oncologists Conduct KRAS Gene Test: Merck Serono
August 30, 2010
- Miraca HD: Sales Up 10.4% to ¥41.4 Bil.
August 30, 2010
- Torii: Anti-HIV Drug Props Up Business
August 30, 2010
- Korosho to Promote Sharing of Knowhow on Use of Generics
August 30, 2010
- Takara Bio: Gene Engineering Segment Struggles
August 30, 2010
- Asahi Kasei Medical Launches New Cell Culture Fluid Filter
August 16, 2010
- Kissei: Pharmaceutical Sales Up 5.9%
August 16, 2010
- Daiichi Sankyo Begins Tender Offer to Acquire Zenotech
August 16, 2010
- PMDA to Directly Investigate Deaths Reported by Med Institutions
August 16, 2010
- Forteo Offers “Aggressive”Treatment for Osteoporosis: Dr Sowa
August 16, 2010
- Nippon Shinyaku: Cialis Props Up Business
August 16, 2010
- Daiichi Sankyo Settles Lawsuit over Evoxac Patent with Apotex
August 16, 2010
- Japan PASS Interim Results for ADVATE Presented
August 16, 2010
- Takeda: Sales, Profits Down due to Lansoprazole Patent Expiration
August 16, 2010
- Fuso: Net Loss despite Increases in Sales
August 16, 2010
- Flu Vaccine Suppliers to Buy Back Med Institutions' Stocks at Their Expense
August 16, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…